Factors Associated with Biosimilar Exclusions and Step Therapy Restrictions Among US Commercial Health Plans

BACKGROUND: Biosimilars have been introduced with the goal of competing with high-priced biologic therapies, yet their adoption has been slower than expected and resulted in limited efficiency gains. We aimed to explore factors associated with biosimilar coverage relative to their reference products...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Tianzhou, Jin, Shihan, Li, Chang, Chambers, James D., Hlávka, Jakub P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10287773/
https://www.ncbi.nlm.nih.gov/pubmed/37004706
http://dx.doi.org/10.1007/s40259-023-00593-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10287773/
https://www.ncbi.nlm.nih.gov/pubmed/37004706
http://dx.doi.org/10.1007/s40259-023-00593-7

Ejemplares similares